ABSTRACT

Background: One of the most lethal contagious diseases is COVID-19, a devastating global pandemic brought on by the SARS-CoV-2 virus. The discovery of therapeutic alternatives has become crucial because to the significant threat to global public health, and a worldwide race to find a cure has mobilised researchers from many disciplines. Scope and approach: The purpose of this study is to assess the therapeutic potential of a number of secondary metabolites like terpenoids, phenolic compounds, alkaloids, glycosides and sulphur-containing compound derived from medicinal plants as inhibitors of SARS-CoV-2 therapeutic targets or as blockers of viral particle entry via host cell receptors. Utilising medicinal plants with specific phytoconstituents may offer the populace a long-term, safer alternative with fewer side effects. Key Findings and Conclusions: Despite the pricey and tedious nature of drug discovery, therapeutic repurposing of current medications was investigated as a therapy option in COVID-19; however, some compounds were withdrawn as therapeutics as a result of either no favourable outcomes or significant adverse effects. These consequences need the investigation of alternative therapy approaches that are both therapeutically effective and safe. Bearing this in mind, phyto-pharmaceuticals produced from medicinal plants might be investigated as essential resources in the development of COVID-19 therapy, since their function in the treatment of viral infections like as HIV, MERS-CoV, and influenza has been extensively documented in the past. Regarding this, many plant-based components, including flavonoids, alkaloids,tannins, and glycosides, among others, have been assessed in this work for their potential to inhibit SARS-CoV-2. Keywords: Antiviral; Coronavirus; Covid-19; Medicinal; Phytoconstituents; SARS-CoV-R
Publication date: 01/09/2025

https://ijbpas.com/pdf/2025/September/MS_IJBPAS_2025_9384.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.9.9384